Zoely: combined oral contraceptive containing new progestogen

Zoely is the first combined oral contraceptive to use nomegestrol as its progesterone component.

Zoely is taken continuously, in 28-day cycles consisting of 24 active therapy days followed by 4 placebo days.
Zoely is taken continuously, in 28-day cycles consisting of 24 active therapy days followed by 4 placebo days.

PHARMACOLOGY

Zoely is a combined oral contraceptive containing nomegestrol acetate, a highly selective progestogen, and estradiol, a natural oestrogen. Nomegestrol acetate has no oestrogenic, androgenic, glucocorticoid or mineralocorticoid activity.1

CLINICAL STUDIES

The safety and efficacy of the estradiol/nomegestrol combination were assessed in two open-label phase III trials, one conducted in Europe and one performed in the US. Participants were randomised to receive 1.5mg estradiol/2.5mg nomegestrol acetate or 30 microgram ethinylestradiol/3mg drospirenone (Yasmin).1

Results

In women aged ≤35 years in the European trial (n=1,757), Pearl Indices (pregnancies per 100 woman-years) were:

  • 0.38 (95% CI 0.10–0.97) for estradiol/nomegestrol, compared with
  • 0.81 for ethinylestradiol/drospirenone (95% CI 0.17–2.35).2

In the US study, Pearl Indices in the same age group (n=1,838) were 1.27 (95% CI 0.66–2.22) and 1.89 (95% CI 0.69–4.11), respectively.3

Safety profile

The estradiol/nomegestrol combination was well tolerated in both studies, with acne and irregular withdrawal bleeding the most common adverse effects.1–3

References

  1. Zoely Summary of Product Characteristics, August 2012.
  2. Mansour D et al. Eur J Contracept Reprod Health Care 2011; 16; 430–43.
  3. Westhoff C et al. Obstet Gynecol 2012; 119: 989–999.

View Zoely drug record
 
Further information: Merck Sharp & Dohme Ltd

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.